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Introduction
Malignant ascites in patients with gynecological malig-
nancies is associated with poor prognosis and poor qual-
ity of life. The bispecific trifunctional antibody removab®
(anti-EpCAM x anti-CD3) belongs to a new class of intact
antibodies that has been developed for targeted therapy of
epithelial tumors. The two binding sites of removab® are
directed against epithelial tumor cells (EpCAM+) and T-
cells (CD3+) thus recruiting T-cells in the direct environ-
ment of tumor cells. Simultaneously, mediated by the
intact Fc-fragment removab® binds to FcγI/IIIR+ accessory
cells (e.g. macrophages, natural killer cells, dendritic cells)
that are mandatory for the induction of a tumor-specific
immune response.
Patients and methods
In an open-label multicenter phase I/II-dose escalating
study, a total of 23 patients with ovarian cancer and symp-
tomatic ascites at FIGO stage III-IV were treated intraperi-
toneally with removab®. The patients had received a
median of 3 (1–8) previous therapies. Their mean age was
62 (42–80) years. The treatment consisted of up to 5 intra-
peritoneal applications of the antibody within 13 days
using increasing dosages.
Results
The intraperitoneal treatment with removab® was able to
stop the production of ascites in 22 of 23 patients. These
patients were ascites-free at the end of the study (day 37).
Immunocytochemical quantification of tumor cells in the
ascites fluid showed a dramatic reduction of EpCAM+ cells
(>log 5). In addition, clinically significant improvement
of the quality of life was observed. The majority of adverse
events was mild to moderate. The most common side
effects observed in the study were fever (82.6%), nausea
(60.9%), vomiting (56.5%), and abdominal pain
(30.4%). The MDT (maximal tolerated dose) was reached
at the increasing dosages of 10 µg–20 µg–50 µg–200 µg–
200 µg.
Conclusion
In conclusion, intraperitoneal treatment with removab®
was safe, well tolerated and showed encouraging efficacy
in patients with malignant ascites due to ovarian cancer.
Thus, the new concept of the anti-EpCAM x anti-CD3 anti-
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body might offer a promising treatment option for
patients with epithelial tumors.Page 2 of 2
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